Lantheus Holdings, Inc. (LNTH) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS
Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings data on Thursday. The medical equipment provider reported $0.24 EPS for the quarter, beating the consensus estimate of $0.20 by $0.04, Bloomberg Earnings reports. Lantheus Holdings had a negative return on equity of 44.05% and a net margin of 9.59%. The business had revenue of $79.94 million for the quarter, compared to the consensus estimate of $77.18 million. During the same quarter in the prior year, the business earned $0.15 earnings per share. Lantheus Holdings’s revenue for the quarter was up 9.4% on a year-over-year basis.
Lantheus Holdings (NASDAQ LNTH) traded up $3.60 during trading on Friday, hitting $22.30. 859,982 shares of the stock traded hands, compared to its average volume of 389,281. The company has a debt-to-equity ratio of -3.05, a current ratio of 2.92 and a quick ratio of 2.43. The stock has a market cap of $847.64 million, a P/E ratio of 20.18, a PEG ratio of 1.65 and a beta of 0.92.
LNTH has been the topic of several research analyst reports. BidaskClub downgraded Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 17th. Jefferies Group LLC reiterated a “buy” rating and issued a $22.00 price objective (up previously from $18.00) on shares of Lantheus Holdings in a research note on Wednesday, August 2nd. Zacks Investment Research downgraded Lantheus Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, September 20th. Credit Suisse Group upped their price objective on Lantheus Holdings from $14.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. Finally, Wells Fargo & Company upgraded Lantheus Holdings from a “market perform” rating to an “outperform” rating in a research note on Thursday. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $20.40.
ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/03/lantheus-holdings-inc-lnth-announces-quarterly-earnings-results-beats-estimates-by-0-04-eps.html.
In related news, insider Michael P. Duffy sold 20,000 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $16.45, for a total value of $329,000.00. Following the sale, the insider now owns 184,218 shares of the company’s stock, valued at approximately $3,030,386.10. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Avista Capital Partners Gp, Ll sold 87,939 shares of the business’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $17.40, for a total value of $1,530,138.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 903,099 shares of company stock worth $15,443,485. 2.30% of the stock is owned by insiders.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.